GlobeNewswire: DIAGNOS Inc. Contains the last 10 of 627 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:40:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/22/2851142/0/en/DIAGNOS-Announces-Closing-of-Second-and-Final-Tranche-of-Private-Placement.html?f=22&fvtc=4&fvtv=43570DIAGNOS Announces Closing of Second and Final Tranche of Private Placement2024-03-22T20:16:47Z<![CDATA[BROSSARD, Quebec, March 22, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a second and final tranche of 650,000 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $182,000, of a non-brokered private placement initially announced on February 27, 2024 (“Private Placement”). Combined with the first closing announced on February 27, 2024, the aggregate number of Units is 2,064,286 and the aggregate gross proceeds amount to $578,000.08.]]>https://www.globenewswire.com/news-release/2024/03/04/2839944/0/en/DIAGNOS-Announces-Grant-of-Stock-Options.html?f=22&fvtc=4&fvtv=43570DIAGNOS Announces Grant of Stock Options2024-03-04T20:45:00Z<![CDATA[BROSSARD, Quebec, March 04, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces a grant of 250,000 stock options to one of its directors, Mr. Michael Braeuel, in connection with his appointment to the Corporation’s board of directors announced by way of news release on February 29, 2024.]]>https://www.globenewswire.com/news-release/2024/03/04/2839944/0/fr/DIAGNOS-annonce-l-octroi-d-options-d-achat-d-actions.html?f=22&fvtc=4&fvtv=43570DIAGNOS annonce l'octroi d'options d'achat d'actions2024-03-04T20:45:00Z<![CDATA[BROSSARD, Québec, 04 mars 2024 (GLOBE NEWSWIRE) -- Diagnos inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK) (OTCQB : DGNOF), un pionnier dans le dépistage précoce de problèmes graves de santé grâce à l’intelligence artificielle (IA), annonce un octroi de 250 000 options d'achat d'actions à l'un de ses administrateurs, M. Michael Braeuel, en lien avec sa nomination au conseil d'administration de la Société annoncée par voie de communiqué le 29 février 2024.]]>https://www.globenewswire.com/news-release/2024/02/29/2838193/0/en/DIAGNOS-Welcomes-Mr-Michael-Braeuel-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=43570DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors2024-02-29T16:10:51Z<![CDATA[BROSSARD, Quebec, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, is pleased to announce the appointment of Mr. Michael Braeuel to the Corporation’s board of directors (the “Board”).]]>https://www.globenewswire.com/news-release/2024/02/29/2838193/0/fr/DIAGNOS-souhaite-la-bienvenue-%C3%A0-M-Michael-Braeuel-au-sein-de-son-conseil-d-administration.html?f=22&fvtc=4&fvtv=43570DIAGNOS souhaite la bienvenue à M. Michael Braeuel au sein de son conseil d'administration2024-02-29T16:10:51Z<![CDATA[BROSSARD, Québec, 29 févr. 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK) (OTCQB : DGNOF), une pionnière de la détection précoce des problèmes de santé critiques grâce à sa plateforme FLAIRE basée sur l'intelligence artificielle (IA), est heureuse d'annoncer la nomination de M. Michael Braeuel au conseil d'administration de la Société (le « conseil »).]]>https://www.globenewswire.com/news-release/2024/02/27/2836465/0/en/DIAGNOS-Announces-Closing-of-First-Tranche-of-Private-Placement.html?f=22&fvtc=4&fvtv=43570DIAGNOS Announces Closing of First Tranche of Private Placement2024-02-27T21:13:48Z<![CDATA[BROSSARD, Quebec, Feb. 27, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a first tranche of 1,414,286 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $396,000.08, of a non-brokered private placement of up to 4,285,714 units, issued at a price of $0.28 per Unit, for gross proceeds of up to $1,200,000 (“Private Placement”). DIAGNOS expects to close a second and final tranche of the Private Placement on March 12, 2024.]]>https://www.globenewswire.com/news-release/2024/02/23/2834641/0/en/Diagnos-Announces-Variation-in-One-Insider-Ownership-of-Common-Shares.html?f=22&fvtc=4&fvtv=43570Diagnos Announces Variation in One Insider Ownership of Common Shares2024-02-23T20:50:00Z<![CDATA[BROSSARD, Québec, Feb. 23, 2024 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX Venture: ADK), announces that on February 20, 2024, Mr. Tristram Coffin (the “Investor”) disposed of 800,000 common shares (each a “Share”) of the Corporation. As a result, since the last Form 62-103F1 was filed, the percentage of the Shares of the Issuer controlled by the Investor decreased by 1.98% on an undiluted basis, and by 2.62% on a partially-diluted basis.]]>https://www.globenewswire.com/news-release/2024/02/21/2832814/0/en/DIAGNOS-recognized-as-a-Top-TSX-Venture-Exchange-Company.html?f=22&fvtc=4&fvtv=43570DIAGNOS recognized as a Top TSX Venture Exchange Company2024-02-21T14:00:00Z<![CDATA[BROSSARD, Quebec, Feb. 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its FLAIRE platform based on Artificial Intelligence (AI), is proud to announce that it has been recognized by the TSX Venture Exchange (the “TSXV” or “the Exchange”) as a 2024 Top 50 Company.]]>https://www.globenewswire.com/news-release/2024/02/21/2832814/0/fr/DIAGNOS-est-reconnue-comme-l-une-des-meilleures-soci%C3%A9t%C3%A9s-de-la-Bourse-de-croissance-TSX.html?f=22&fvtc=4&fvtv=43570DIAGNOS est reconnue comme l'une des meilleures sociétés de la Bourse de croissance TSX2024-02-21T14:00:00Z<![CDATA[BROSSARD, Québec, 21 févr. 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (« DIAGNOS » ou la « Société ») (Bourse de croissance TSX : ADK) (OTCQB : DGNOF), pionnière de la détection précoce des problèmes de santé critiques grâce à sa plateforme FLAIRE basée sur l'intelligence artificielle (IA), est fière d'annoncer qu'elle a été reconnue par la Bourse de croissance TSX (la « TSXV » ou « la Bourse ») comme l'une des 50 meilleures sociétés 2024.]]>https://www.globenewswire.com/news-release/2024/01/16/2810056/0/en/DIAGNOS-Appoints-New-Chief-Operating-Officer.html?f=22&fvtc=4&fvtv=43570DIAGNOS Appoints New Chief Operating Officer2024-01-16T15:00:00Z<![CDATA[BROSSARD, Quebec, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, is pleased to announce the appointment of Mr. Yves-Stéphane Couture as Chief Operating Officer. As part of his duties, Mr. Couture will be responsible for the continuous development of our flagship product CARA as well as its commercialization worldwide.]]>